Syndax Pharmaceuticals presents positive data on revumenib for post-transplant leukemia maintenance

hk.investing.com (Chinese)

Syndax Pharmaceuticals presented data on revumenib's use in post-transplant leukemia maintenance therapy. The data, shared at the ASCO 2026 meeting, showed a 90% two-year overall survival rate for patients receiving revumenib after stem cell transplant. This is a significant improvement over historical control groups. Revumenib is approved for relapsed or refractory KMT2A-altered or NPM1-mutated acute leukemias. The company's revenue has seen substantial growth, with analysts predicting continued sales increases.


With a significance score of 2.9, this news ranks in the top 13% of today's 33817 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Syndax Pharmaceuticals presents positive data on revumenib for post-transplant leukemia maintenance | News Minimalist